Genenta signs Definitive Agreements with Sophia High Tech

Genenta Science (Nasdaq: GNTA), transforming into Saentra Forge, has signed definitive agreements to invest €6.0 million in Sòphia High Tech, an Italian aerospace and defense manufacturer. The investment will give Genenta a 19.9% stake initially and 51% stake upon second tranche closing. Sòphia HT, which reported €6.29 million in 2024 revenues and €0.96 million EBITDA, expects to double revenues by 2027 while expanding its workforce from 44 to 70 employees.

04/23/2026, 7:00 AM • GlobeNewswire

Genenta, evolving into Saentra Forge, has signed a Binding Offer with Sòphia High Tech, an Italian company manufacturing critical parts for Europe's space and defense programs

Genenta Science, transitioning to Saentra Forge, has entered into a binding offer to acquire Italian aerospace and defense manufacturer Sòphia High Tech through two reserved capital increases totaling EUR 6.0 million, with the goal of reaching a controlling stake upon achieving defined performance milestones. Sòphia High Tech, founded in 2013 and headquartered in Naples, specializes in precision mechanical components for space and defense applications, serving major European clients including ESA, Leonardo, MBDA, and Thales Alenia Space.

03/27/2026, 5:00 AM • GlobeNewswire

Genenta Advances Transformation into Saentra Forge, Strengthens ATC Governance and Expands Strategic Industrial Consolidation Platform

Genenta Science (Nasdaq: GNTA), transforming into Saentra Forge (Nasdaq: SAEN), announced the appointment of Paolo Salvato to ATC's Board of Directors and is pursuing majority-control acquisitions in national-security sectors including defense, aerospace, and cybersecurity. The company also announced that Nature Medicine accepted a manuscript on clinical results from its Glioblastoma trial, representing validation of its biotech program while seeking strategic partnerships for further development.

02/27/2026, 4:00 AM • GlobeNewswire

Genenta Reports Long-Term Survival Trends and Immune Findings in Brain Tumor (GBM) Trial

Genenta Science reported positive survival metrics in its TEM-GBM study for glioblastoma patients, with 44% reaching 18-month survival and one patient surviving 39 months after treatment. The company also announced approximately $30 million in cash and short-term investments following a recent direct offering.

11/24/2025, 4:00 AM • GlobeNewswire

Genenta Announces Pricing of $15.0 Million Registered Direct Offering of American Depositary Shares

Genenta Science has entered into a securities purchase agreement to sell 4,285,715 American Depositary Shares at $3.50 per share, raising approximately $15 million for working capital and general corporate purposes.

10/26/2025, 8:30 PM • GlobeNewswire

Genenta and Anemocyte Announce Strategic Partnership to Advance Off-The-Shelf LVV Plasmid DNA Production

Genenta Science and Anemocyte have formed a strategic partnership to advance lentiviral vector (LVV) plasmid DNA technology, expanding their existing collaboration to provide high-quality materials for advanced therapy programs.

10/24/2025, 4:00 AM • GlobeNewswire